Afferent Pharmaceuticals
Advancing the science of chronic pain relief by targeting P2X3 receptors in nerve fibers
Advancing the science of chronic pain relief by targeting P2X3 receptors in nerve fibers
Afferent Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on developing treatments for chronic pain by targeting P2X3 receptors in nerve fibers. The company's key development, AF-219, has completed two Phase 1 clinical studies. Founded in 2009, Afferent Pharmaceuticals is based in San Mateo, California. In July 2015, the company received a $55.00M Series C investment from investors including New Leaf Venture Partners, Redmile Group, Fidelity, PFM Health Sciences, Jennison Associates, Tekla Capital Management. The company's slogan, "Advancing the science of chronic pain relief by targeting P2X3 receptors in nerve fibers," reflects its commitment to medical innovation in the biopharma, biotechnology, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $55.00M | 6 |
|
08 Jul 2015 |
| Series B | $5.00M | 3 |
|
01 Apr 2013 |
| Series A | $23.00M | 1 |
|
16 Dec 2009 |
| Convertible Note | $150.00K | - | 23 Oct 2009 |
No recent news or press coverage available for Afferent Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
